The Life Sciences Virtual Investor Forum, co-hosted by Zacks Small-Cap Research and B2i Digital, Inc., will take place over two days on June 24 and 25, 2026, featuring presentations from more than 20 publicly traded companies across biotechnology, diagnostics, medical devices, and digital health. The forum aims to provide investors with direct access to management teams through live presentations, real-time Q&A, and one-on-one meetings.
B2i Digital, acting as the Official Marketing Partner, brings the forum into its ecosystem, leveraging a distribution and media engine that reaches a proprietary network of more than 1.7 million retail and institutional market participants. This visibility engine has supported over 115 investor conferences, and the company’s mantra, "From Marketing to Meetings℠," reflects its integrated approach to connecting investors with companies.
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, prepares independent company-sponsored research and related content. Its team of life sciences analysts co-hosts the forum, adding credibility and depth to the event. "Life sciences investors want efficient, direct access to management teams developing the therapies and technologies that matter, and pairing that access with independent research from Zacks makes the forum more valuable on both sides," said David Shapiro, Chief Executive Officer of B2i Digital.
The two-day lineup spans a wide range of sectors, including clinical-stage biotechnology, rare-disease and oncology therapeutics, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health. Presenting companies on Day One (June 24) include Protalix BioTherapeutics, MetaVia Inc., CytoSorbents Corporation, PetVivo Holdings Inc., Jaguar Health, Inc., Reviva Pharmaceuticals Holdings, Inc., and 4DMedical Ltd. Day Two (June 25) features Prostatype Genomics AB, Abingdon Health plc, Innovotech, Inc., Lakewood-Amedex Biotherapeutics Inc., Nasus Pharma Ltd., Kelyniam Global, Inc., IMUNON, Inc., Promino Nutritional Sciences Inc., Envoy Medical Inc., Coiled Therapeutics plc, Aspire Biopharma Holdings Inc., Rocket Doctor AI Inc., Phio Pharmaceuticals Corp., aTyr Pharma, Inc., and NuFarm Ltd.
Each company is allocated 30 minutes for a live presentation and Q&A session. Investors can request one-on-one meetings with management through the Virtual Investor Conferences (VIC) site at this link. Replays of presentations will be available on B2i Digital and OTC Markets YouTube channels.
Registration and company profiles are available at Virtual Investor Conferences. Throughout the year, Virtual Investor Conferences feature public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets. Virtual Investor Conferences is an OTC Markets Group Inc. property.
The forum underscores the growing importance of direct investor access to life sciences companies, particularly in an environment where capital efficiency and research-driven decision-making are critical. By combining B2i Digital's marketing reach with Zacks' independent research, the event aims to bridge the gap between innovation and investment, enabling investors to make informed decisions about emerging therapies and technologies.
For more details about B2i Digital and its programs, visit B2i Digital.
